These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
215 related items for PubMed ID: 26190453
1. Influenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDs. Michel M, Vincent FB, Rio S, Leon N, Marcelli C. Joint Bone Spine; 2016 Mar; 83(2):237-8. PubMed ID: 26190453 [No Abstract] [Full Text] [Related]
2. Seasonal influenza vaccine coverage of patients on biotherapy for inflammatory joint disease in Normandy, France. Michel M, Vincent FB, Rio S, Leon N, Marcelli C. Joint Bone Spine; 2016 Jul; 83(4):465-7. PubMed ID: 26453110 [No Abstract] [Full Text] [Related]
3. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register. Lie E, Fagerli KM, Mikkelsen K, Rødevand E, Lexberg A, Kalstad S, Uhlig T, Kvien TK. Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896 [No Abstract] [Full Text] [Related]
9. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. Iannone F, Salaffi F, Fornaro M, Di Carlo M, Gentileschi S, Cantarini L, Lopalco G. Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593 [Abstract] [Full Text] [Related]
10. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. Blumentals WA, Arreglado A, Napalkov P, Toovey S. BMC Musculoskelet Disord; 2012 Aug 27; 13():158. PubMed ID: 22925480 [Abstract] [Full Text] [Related]
13. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis. Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ. Clin Ther; 2016 May 27; 38(5):1205-16. PubMed ID: 27045991 [Abstract] [Full Text] [Related]
14. Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study. Brocq O, Acquacalda E, Berthier F, Albert C, Bolla G, Millasseau E, Destombe C, Azulay J, Asquier C, Florent A, Le Seaux S, Euller-Ziegler L. Joint Bone Spine; 2016 Mar 27; 83(2):155-9. PubMed ID: 26725745 [Abstract] [Full Text] [Related]
16. Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis. Gossen N, Jacob L, Kostev K. Rheumatol Int; 2016 Aug 27; 36(8):1113-8. PubMed ID: 26936261 [Abstract] [Full Text] [Related]
17. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA. Curr Med Res Opin; 2006 Jan 27; 22(1):169-83. PubMed ID: 16393443 [Abstract] [Full Text] [Related]
19. Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis. Kelly A, Tymms K, Tunnicliffe DJ, Sumpton D, Perera C, Fallon K, Craig JC, Abhayaratna W, Tong A. Arthritis Care Res (Hoboken); 2018 Apr 27; 70(4):525-532. PubMed ID: 28732151 [Abstract] [Full Text] [Related]